TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27145355

Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (8-week program)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Attention control arm
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Number of subjects: 43
Study: 25728739

Group type: EXPERIMENTAL
Intervention: Gradual tapering of desmopressin (ODM) - Group B: 240 μg ODM per day → 120 μg ODM per day → 120 μg ODM per alternate day → cessation
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Gradual tapering of desmopressin (ODM) - Group C: 240 μg ODM per day → 120 μg ODM per day → 60 μg ODM per day → 60 μg ODM per alternate day → cessation
Number of subjects: 157
Study: 23870444

Group type: EXPERIMENTAL
Intervention: Curriculum-based measurement (CBM)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Teacher ratings using Performance Screening Guides (PSGs)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Performance Screening Guides (PSGs)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Both screening methods (CBM and PSGs)
Number of subjects: 413
Study: 21460676

Group type: EXPERIMENTAL
Intervention: Injectable poly-L-lactic acid
Number of subjects: 233

Group type: COMPARATOR
Intervention: Human collagen
Number of subjects: 233
Study: 19778676

Group type: EXPERIMENTAL
Intervention: Septal reduction
Number of subjects: 25

Group type: COMPARATOR
Intervention: HOCM patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: HCM patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 25
Study: 16945890

Group type: EXPERIMENTAL
Intervention: Ultrasonic scaling + subgingival irrigation with 0.5% PVP-iodine for 5 min/tooth
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ultrasonic scaling + subgingival irrigation with sterile saline solution for 5 min/tooth
Number of subjects: 20

Group type: COMPARATOR
Intervention: Subgingival irrigation with sterile saline solution for 5 min/tooth
Number of subjects: 20

Group type: COMPARATOR
Intervention: Subgingival irrigation with 0.5% PVP-iodine for 5 min/tooth
Number of subjects: 20
Study: 15238098

Group type: EXPERIMENTAL
Intervention: New topical formulation (0.25% alpha-glucosylrutin, 1% tocopheryl acetate, SPF 15 sunscreen)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sunscreen-only gel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11174807

Group type: EXPERIMENTAL
Intervention: Aorto-uni-iliac endograft (A-I)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Bifurcated endograft (BI)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Tube endograft (T)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Open control (C)
Number of subjects: 121
Study: 9036799

Group type: EXPERIMENTAL
Intervention: Seronegative donor and recipient
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Seronegative donor and seropositive recipient
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Seropositive donor and recipient
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Seropositive donor and seronegative recipient
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Retransplantation
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Total number of units of blood products administered during transplantation
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Presence of CMV disease
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Invasive fungal disease
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Bacteremia
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Donor and recipient CMV serologic status
Number of subjects: 146
Study: 7932425

Group type: EXPERIMENTAL
Intervention: Nabumetone, 1000 mg nightly
Number of subjects: 52

Group type: COMPARATOR
Intervention: Naproxen, 250 mg twice daily
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 52

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 52
Study: 3278942

Group type: EXPERIMENTAL
Intervention: 1-g 5-aminosalicylic acid enemas
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo enemas
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 1-g 5-aminosalicylic acid enemas (second trial)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (second trial)
Number of subjects: 25
Study: 30952534

Group type: EXPERIMENTAL
Intervention: Pre-diabetic participants
Number of subjects: 5792

Group type: EXPERIMENTAL
Intervention: Diabetic participants
Number of subjects: 5792

Group type: COMPARATOR
Intervention: Non-diabetic participants
Number of subjects: 5792
Study: 31507253

Group type: EXPERIMENTAL
Intervention: Intensive short-term dynamic psychotherapy (30-day inpatient program)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 62
Study: 27546011

Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Number of subjects: 272

Group type: COMPARATOR
Intervention: Fluorouracil-only
Number of subjects: 272
Study: 24753507

Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 20
Study: 23766412

Group type: EXPERIMENTAL
Intervention: 0.3 mg ramosetron combined with 75 µg/kg midazolam (Group RM)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.3 mg ramosetron (Group R)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 75 µg/kg midazolam (Group M)
Number of subjects: 100
Study: 22043673

Group type: EXPERIMENTAL
Intervention: Superficial needling at corresponding myofascial fasciae trigger point (MTrP) followed by acupuncture at Jiaji (EX‐B 2) for 30 min.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Superficial needling only (control group).
Number of subjects: 60
Study: 18504090

Group type: EXPERIMENTAL
Intervention: Double-dose immediate-release morphine (DD)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Single-dose immediate-release morphine (SD)
Number of subjects: 19
Study: 16388973

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) in addition to best medical treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Best medical treatment alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 120
Study: 15130906

Group type: COMPARATOR
Intervention: Smokers with > 10 pack-years
Number of subjects: 232

Group type: COMPARATOR
Intervention: Smokers with > 20 pack-years
Number of subjects: 232

Group type: COMPARATOR
Intervention: Smokers with > 30 pack-years and DL(CO) < 60% predicted
Number of subjects: 232

Group type: COMPARATOR
Intervention: Smokers with early stages of smoking-induced lung disease
Number of subjects: 232

Group type: COMPARATOR
Intervention: Smokers with advanced stages of smoking-induced lung disease
Number of subjects: 232
Study: 11117501

Group type: EXPERIMENTAL
Intervention: Standardized visual task
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Standardized motor task
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Standardized visual and motor tasks
Number of subjects: 6
Study: 9187599

Group type: EXPERIMENTAL
Intervention: Routine chest radiographs
Number of subjects: 80
Study: 7506162

Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 46

Group type: COMPARATOR
Intervention: Ketoprofen
Number of subjects: 46
Study: 3070611

Group type: EXPERIMENTAL
Intervention: i.v. naloxone (20 mg, 40 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 28985265

Group type: EXPERIMENTAL
Intervention: Invasive strategy (n = 229) involving early coronary angiography, with immediate evaluation for percutaneous coronary intervention, coronary artery bypass graft, optimal medical therapy.
Number of subjects: 457

Group type: COMPARATOR
Intervention: Conservative strategy (n = 228).
Number of subjects: 457
Study: 26690634

Group type: EXPERIMENTAL
Intervention: Alcohol prime (0.6 g of alcohol per kg of body weight)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo drink manipulated to smell and taste alcoholic
Number of subjects: 60
Study: 25910919

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H5N1 vaccine (3.75μg of hemagglutinin antigen, two doses given 21 days apart)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H5N1 vaccine
Number of subjects: 81

Group type: COMPARATOR
Intervention: TIV (licensed seasonal inactivated trivalent influenza vaccine)
Number of subjects: 81
Study: 23994934

Group type: EXPERIMENTAL
Intervention: Actovegin (5 ml, 200 mg daily for 4 weeks)
Number of subjects: 30
Study: 15782622

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha‐2b (Peg‐IFN‐alpha2b) plus ribavirin
Number of subjects: 64

Group type: COMPARATOR
Intervention: Leucocyte interferon alpha (IFN‐alpha) plus ribavirin
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: EVR at week 4
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: EVR after more than 4 weeks of therapy
Number of subjects: 64
Study: 12701935

Group type: EXPERIMENTAL
Intervention: Higher daily doses of inhaled corticosteroids (iCSTs) (>= 400 microg)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Emergency department visits
Number of subjects: 97

Group type: COMPARATOR
Intervention: Total asthma-related costs
Number of subjects: 97
Study: 10214535

Group type: EXPERIMENTAL
Intervention: zolmitriptan 5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: dexfenfluramine 15 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 8529780

Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg on day 1 followed by 100 mg daily or 200 mg daily
Number of subjects: 210

Group type: COMPARATOR
Intervention: Co-amoxiclav 500 mg three times daily
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Crossed over to alternative antibiotic
Number of subjects: 210

Group type: COMPARATOR
Intervention: Co-amoxiclav
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 210
Study: 2325052

Group type: EXPERIMENTAL
Intervention: Misoprostol with indomethacin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Misoprostol plus indomethacin
Number of subjects: 10
Study: 220656

Group type: EXPERIMENTAL
Intervention: ACTH 4-10 (30 mg, s.c.)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 18
Study: 31512746

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 0
Study: 30478131

Group type: EXPERIMENTAL
Intervention: Namaste Care intervention delivered at nursing care home level
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 27562137

Group type: EXPERIMENTAL
Intervention: Metronomic prednisone, etoposide, and cyclophosphamide
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional salvage chemotherapy
Number of subjects: 44
Study: 26591359

Group type: EXPERIMENTAL
Intervention: Xinfeng Capsule (XC), three pills each time, three times daily for two therapeutic courses (one month each).
Number of subjects: 180

Group type: COMPARATOR
Intervention: Methotrexate Tablet, four tablets each time, once per week for two therapeutic courses (one month each).
Number of subjects: 180

Group type: COMPARATOR
Intervention: Healthy control group (60 patients), no intervention specified.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Xinfeng Capsule (XC) vs Methotrexate Tablet after treatment.
Number of subjects: 180
Study: 23064844

Group type: EXPERIMENTAL
Intervention: Work-site strength-training program
Number of subjects: 427

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 427
Study: 20103757

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 167

Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy (ADT)
Number of subjects: 167
Study: 18771543

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no CPAP therapy)
Number of subjects: 28
Study: 16299866

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (1 mg/dose)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide
Number of subjects: 67
Study: 12297769

Group type: EXPERIMENTAL
Intervention: Preoperative endoscopic biliary stent placement
Number of subjects: 337

Group type: COMPARATOR
Intervention: No endoscopic biliary stent placement (control)
Number of subjects: 337
Study: 10327029

Group type: COMPARATOR
Intervention: Epirubicin 100 mg/m2 plus cisplatin 75 mg/m2 q 4 weeks
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 500 mg/m2 plus epirubicin 75 mg/m2 plus cisplatin 50 mg/m2 q 4 weeks
Number of subjects: 210
Study: 8536451

Group type: EXPERIMENTAL
Intervention: FlexiGard
Number of subjects: 4286

Group type: COMPARATOR
Intervention: TCu 380A
Number of subjects: 4286
Study: 1827613

Group type: EXPERIMENTAL
Intervention: 200 mg of etodolac twice daily
Number of subjects: 39

Group type: COMPARATOR
Intervention: 500 mg of naproxen twice daily
Number of subjects: 39
Study: 7028941

Group type: EXPERIMENTAL
Intervention: surgical pocket elimination or reduction
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: modified Widman flap surgery
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: subgingival curettage
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: scaling and root planing only
Number of subjects: 90
Study: 30276598

Group type: EXPERIMENTAL
Intervention: Mindset intervention
Number of subjects: 598

Group type: COMPARATOR
Intervention: Control activities
Number of subjects: 598
Study: 28672273

Group type: EXPERIMENTAL
Intervention: Parent-administered early intervention program
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 130
Study: 25917876

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg/day
Number of subjects: 1103

Group type: COMPARATOR
Intervention: Enzalutamide
Number of subjects: 1103
Study: 23377369

Group type: EXPERIMENTAL
Intervention: Modified staircase method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ascending 3-alternative forced-choice method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both methods
Number of subjects: 0
Study: 21271357

Group type: EXPERIMENTAL
Intervention: Be Under Your Own Influence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Above the Influence
Number of subjects: 0
Study: 19899578

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 25
Study: 17285571

Group type: EXPERIMENTAL
Intervention: Various treatments for GERD
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bayesian hierarchical models
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Models for absolute treatment effects
Number of subjects: 6
Study: 15132728

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg once daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Oestradiol valerate (2 mg daily) and dydrogesterone (20 mg daily for 2 weeks every 3 months)
Number of subjects: 31
Study: 11490695

Group type: EXPERIMENTAL
Intervention: Automix light viscosity material
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Automix regular viscosity material
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tubed light viscosity material
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tubed regular viscosity material
Number of subjects: 100
Study: 9589508

Group type: EXPERIMENTAL
Intervention: Social support (number of persons in support system)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Aversive social contact
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Pain intensity
Number of subjects: 102
Study: 8026230

Group type: EXPERIMENTAL
Intervention: Left hemicolectomy
Number of subjects: 270

Group type: COMPARATOR
Intervention: Left segmental colectomy
Number of subjects: 270
Study: 2777438

Group type: EXPERIMENTAL
Intervention: n.100 m
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 2.100 m
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: n.300 m
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 2.400 m
Number of subjects: 11

Group type: COMPARATOR
Intervention: n.300 m and 2.400 m
Number of subjects: 11
Study: 1108176

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 36

Group type: COMPARATOR
Intervention: Tetracycline hydrochloride
Number of subjects: 36
Study: 31178152

Group type: EXPERIMENTAL
Intervention: 6-month trastuzumab treatment (loading dose of 8 mg/kg followed by maintenance doses of 6 mg/kg)
Number of subjects: 4089

Group type: COMPARATOR
Intervention: 12-month trastuzumab treatment (loading dose of 8 mg/kg followed by maintenance doses of 6 mg/kg)
Number of subjects: 4089

Group type: EXPERIMENTAL
Intervention: 6-month trastuzumab treatment
Number of subjects: 4089

Group type: COMPARATOR
Intervention: 12-month trastuzumab treatment
Number of subjects: 4089
Study: 28345809

Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25894275

Group type: EXPERIMENTAL
Intervention: Genomic information
Number of subjects: 200

Group type: COMPARATOR
Intervention: Behavioral information
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Supportive communication approach
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Directive communication approach
Number of subjects: 200
Study: 22608115

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behaviour therapy (ICBT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Attention control condition (CC)
Number of subjects: 81
Study: 20629665

Group type: EXPERIMENTAL
Intervention: Ascorbic acid infusion
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 18637755

Group type: EXPERIMENTAL
Intervention: Single-day famciclovir (1000 mg administered twice daily)
Number of subjects: 1179

Group type: COMPARATOR
Intervention: 3-day valacyclovir (500 mg administered twice daily)
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: Single-day famciclovir
Number of subjects: 1179

Group type: COMPARATOR
Intervention: 3-day valacyclovir
Number of subjects: 1179
Study: 17039234

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (alloSCT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Autologous stem cell transplantation (autoSCT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 58
Study: 12953944

Group type: EXPERIMENTAL
Intervention: Combination of benzoyl peroxide 6% cleanser and tretinoin 0.1% microsphere gel
Number of subjects: 87

Group type: COMPARATOR
Intervention: Tretinoin 0.1% microsphere gel (monotherapy)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 87
Study: 10994910

Group type: EXPERIMENTAL
Intervention: Light exercise (50 biceps curls with a 5-lb dumbbell)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Immobilization (arm casted and supported in a sling at 90 degrees)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (no restriction of arm activity)
Number of subjects: 26
Study: 8836273

Group type: EXPERIMENTAL
Intervention: 4 micrograms kg-1 clonidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2 micrograms kg-1 clonidine
Number of subjects: 60
Study: 1442855

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nitrendipine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 48

Group type: COMPARATOR
Intervention: Diuretic
Number of subjects: 48
Study: 3971296

Group type: EXPERIMENTAL
Intervention: Pump therapy
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Resection plus pump
Number of subjects: 65

Group type: COMPARATOR
Intervention: Pump only
Number of subjects: 65

Group type: COMPARATOR
Intervention: Resection of metastases
Number of subjects: 65

Group type: COMPARATOR
Intervention: Unresectable disease with positive portal nodes
Number of subjects: 65
Study: 30140899

Group type: EXPERIMENTAL
Intervention: Natriuretic peptides (log-transformed and standardized, expressed per 1 SD, z score)
Number of subjects: 1057
Study: 26808146

Group type: EXPERIMENTAL
Intervention: Pressure stimulation (120% PPT) for 5 seconds
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pressure stimulation (120% PPT) for 60 seconds
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Saline-induced pain
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Delayed onset muscle soreness (eccentric exercise)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Day 2 assessments compared to Day 1
Number of subjects: 20
Study: 24699551

Group type: EXPERIMENTAL
Intervention: Intracoronary Adenosine (100 µg/stented vessel)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard PCI
Number of subjects: 100
Study: 22040605

Group type: COMPARATOR
Intervention: Living-room theatre activity by professional actors (E2)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Living-room theatre activity by trained professional caregivers (E1)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Usual reminiscence group activity (Control)
Number of subjects: 131
Study: 20353387

Group type: EXPERIMENTAL
Intervention: Genotype (GT) test
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Combined phenotype-genotype test (PGT)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Tipranavir
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Darunavir
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Other PIs
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: New regimen with two or more active agents
Number of subjects: 246
Study: 17506739

Group type: EXPERIMENTAL
Intervention: Airtraq device
Number of subjects: 7

Group type: COMPARATOR
Intervention: Direct laryngoscopy with Macintosh blade
Number of subjects: 7
Study: 15837451

Group type: EXPERIMENTAL
Intervention: anti-cyclooxygenase-2 non-steroidal anti-inflammatory drugs (anti-COX-2 NSAIDs)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Number of daily tablets of study medication
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Frequency of clinical visits
Number of subjects: 212
Study: 11913886

Group type: EXPERIMENTAL
Intervention: timolol + brimonidine
Number of subjects: 20

Group type: COMPARATOR
Intervention: timolol + placebo
Number of subjects: 20
Study: 9466539

Group type: EXPERIMENTAL
Intervention: PFP-2 vaccine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (influenza vaccine)
Number of subjects: 21